Ponce Therapeutics is at the forefront of developing innovative longevity technologies aimed at addressing the fundamental mechanisms of aging. Their flagship product, Yuuth™, is designed to combat "inflammaging" by targeting and eliminating senescent cells, which are known to contribute to the aging process. The company employs advanced biotechnology platforms to create novel therapeutics that restore a youthful balance between aged and young cells, particularly in the skin. Their approach includes both senolytic and senomorphic strategies, which focus on either eliminating senescent cells or modifying their secretory profiles to reduce inflammation and rejuvenate tissues.

The company is also actively pursuing research and development programs that target aging-associated skin disorders, specifically focusing on p16-expressing senescent cells. This focus not only aims to improve skin health but also has potential implications for treating conditions like Bowen's disease, which shares similar cellular characteristics. Ponce Therapeutics is leveraging its scientific expertise and state-of-the-art facilities in Houston, Texas, to advance its clinical pipeline and develop a comprehensive portfolio of anti-aging products grounded in rigorous scientific research.

United States

Ponce Therapeutics is developing a state-of-the-art biotechnology platform to restore the youthful balance of aged or “senescent” and young cells in your skin, targeting the senescent cells for elimination. This provides a “reboot” of your genetic program to turn the clock on your skin back to its youthful exuberance.

Cancer

Skin Diseases

Ponce Therapeutics

Actinic keratosis

Skin cancer

Drug #1 (Senescent cells - Selective Elimination)

Biologics

Skin disease/disorder

Drug #2 (Senescent cells - Foxo4-p53 (miRs))

Age-related diseases

Drug #3 (Foxo4-p53 (SPs))

Drug #4 (Pan-TKI)

Breast cancer

Drug #5 (Estrogen receptor (ERa))

Florida

Small Molecule Pharmaceuticals

Therapeutic

Ponce Therapeutics

Company Details